Analytical Data
-
Gene name
CHRDL2
- Application
-
Alternative Names
BNF1; CHL2; Breast Tumor Novel Factor 1; Chordin-related protein 2
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8VEA6
-
Expression Region
Ser27~Ser169
-
Molecular Weight
18&20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CHRDL2, or Chordin-like protein 2, is a member of the Chordin family of proteins, which play critical roles in embryonic development and the regulation of bone morphogenetic proteins (BMPs). This protein is primarily expressed in the central nervous system and has been implicated in various developmental processes, including neural differentiation and tissue patterning. Research has shown that CHRDL2 may act as a BMP antagonist, modulating signaling pathways that are crucial for organogenesis and maintaining tissue homeostasis. Given its involvement in these fundamental biological processes, CHRDL2 has garnered attention as a potential therapeutic target in regenerative medicine and neurodevelopmental disorders. The study of recombinant CHRDL2 proteins allows researchers to investigate its functional properties in detail, elucidate its mechanisms of action, and explore its role in disease pathogenesis. Advances in recombinant technology have facilitated the production and purification of CHRDL2, enabling systematic analyses of its interactions with other signaling molecules and effects on cellular behavior. Ongoing studies aim to uncover the precise biological functions of CHRDL2 and its potential applicability in developing novel treatment strategies for disorders where BMP signaling is disrupted, such as certain cancers or degenerative diseases. Through this research, a deeper understanding of CHRDL2's role in development and disease may emerge, paving the way for innovative therapeutic interventions.
